Ideas to life
Image
A little about us
What we do
At UniServices, we bring ideas to life. We partner with the best minds in business and academia to apply intelligent thinking to ideas that have the potential to change the world.
What we are working on
Who we help
Together with our partners, we look to the future, imagine the possibilities, and innovate for public and private good. For nearly 30 years, we've collaborated with hundreds of organisations on thousands of projects in New Zealand and around the world.
Some of the people we work with
What we're working on
The University of Auckland Innovation Institute China (UOAIIC) opened this month to develop and commercialise its research and to provide a springboard for innovative New Zealand companies and researchers to collaborate and tap into the local market.
UniServices news
UniServices has signed a multi-million-dollar deal that will allow a significant increase in the number and quality of world class “disruptive” companies spun out of the university’s research and development.
It is part of an agreement that will see Auckland and the Group of Eight (Go8*) Australian universities together receive investment of “at least” NZ$215 million over 10 years to find and develop companies involved in “disruptive innovation” in areas such as digital medicine, new medical therapies and quantum computing.
The University of Auckland’s new Innovation Institute China (UAIIC) will provide unprecedented access to an extensive range of networks, research and funding opportunities in China.
The University of Auckland’s knowledge transfer company, UniServices, has established the institute in the Chinese city of Hangzhou. It is due to formally open in the first quarter of 2017 and will focus on collaboration.
The Innovation Institute will allow the University of Auckland, UniServices and its partners to:
UniServices and the University of Auckland are partnering with an American drug development company to launch a biotech start-up that will research novel cancer vaccines.
The new start-up, SapVax was formed by scientists from the University of Auckland and BioMotiv, an accelerator company in Cleveland, Ohio, that is part of a $300 million initiative for advancing medicine called The Harrington Project for Discovery & Development.
SapVax will develop a suite of first-in-class cancer vaccines based on a novel peptide platform technology.